ADDING and REPLACING Alfa Wassermann Proteomic Technologies, LLC Announces an Agreement to Jointly Develop Methodologies in Collaboration with Pressure BioSciences, Inc.

WEST CALDWELL, N.J. -- Reissuing release to add ticker symbol for searching purposes.

The release reads:

ALFA WASSERMANN PROTEOMIC TECHNOLOGIES, LLC ANNOUNCES AN AGREEMENT TO JOINTLY DEVELOP METHODOLOGIES IN COLLABORATION WITH PRESSURE BIOSCIENCES, INC.

Alfa Wassermann Proteomic Technologies, LLC, (AWPT), a division of Alfa Wassermann Inc, announces an agreement with Pressure BioSciences, Inc, (NASDAQ:PBIO) to jointly develop sample preparation methodologies that enrich for low abundance proteins and subcellular organelles from cells and tissues. Alfa Wassermann Proteomic Technologies (AWPT) will utilize PBI's novel, enabling, and patented Pressure Cycling Technology (PCT) to enhance techniques for cell disruption, specifically for the preparation of samples prior to downstream processing with the AW Promatix 1000[TM].

PBI's Pressure Cycling Technology Sample Preparation System (PCT SPS) allows for precisely controlled, rapid, and reproducible cell disruption from a wide variety of cells and tissues. The AW Promatix 1000[TM] is capable of automated fractionation of organelles and sub-cellular moieties. To this end, the AW Promatix 1000[TM] provides highly enriched fractions of organelles and sub-cellular particles, thereby delivering more low abundance proteins and making thorough proteome studies and first-time discoveries a possibility. The collaboration between AWPT and PBI looks to combine PBI's PCT SPS with the AW Promatix 1000 in an effort to provide the research community with a sample preparation and processing method with significantly enhanced capabilities when compared to currently used techniques.

Dino DiCamillo, President of Alfa Wassermann Proteomic Technologies, said: "Our initial success with the Pressure BioSciences's PCT SPS led AWPT to formalize an agreement. Our intent is to develop tissue disruption methods to better enable users of the AW Promatix 1000[TM] across a number of relevant tissue and cell types. Our technology coupled with effective sample preparation will lead to improved fractionation, isolation, and enrichment of organelles and low abundance proteins. We are very excited to enter this phase of our relationship."

Richard T. Schumacher, President and CEO of Pressure BioSciences, commented: "This collaboration extends our research and development focus on the reproducible and precise extraction of biomolecules with alternating high and low hydrostatic pressure. The ability to fractionate subcellular complexes using AWPT's technology enhanced by the consistent and tightly controlled cell disruption by PCT SPS should help researchers better understand cellular regulation and function, which in turn may lead to the discovery of better drugs against such devastating illnesses as infectious, oncologic (cancer), neurodegenerative, and heart diseases."

About AWPT, LLC

Established in January 2004 as a division of Alfa Wassermann, Inc. (AWI), AWPT leverages and builds upon AWI's established continuous flow ultracentrifugation technologies to develop products that significantly improve the quality and reduce the complexity of cellular organelles and macromolecules for proteomic analysis. AWPT recently introduced AW Promatix[TM] - a continuous-flow ultracentrifugation system that employs buoyant density accumulation to automate the separation, fractionation and enrichment of sub-cellular particles in a single step.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

About Alfa Wassermann, Inc.

AWI has provided high quality products and services to the health care community since 1960. For more than 35 years, Alfa Wassermann Separation Technologies, LLC has been a world leader in separations technology with a line of ultracentrifuges employed for commercial production of vaccines and other research applications. In the 1960s, Alfa Wassermann (then Electro-Nucleonics Inc., or ENI) became the first company to commercially introduce the technology of continuous-flow zonal ultracentrifugation to the biopharmaceutical manufacturing marketplace. Alfa Wassermann Diagnostic Technologies, LLC provides reliable and fully integrated clinical chemistry systems and reagents to laboratories in the clinical diagnostic and veterinary marketplace as well as the life sciences market.

Forward Looking Statements:

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "should", "planned", and "expect", among others. These forward-looking statements are based on Alfa Wassermann's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Alfa Wassermann notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. All information in this press release is as of the date of the release, and Alfa Wassermann does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

[c]2006. Alfa Wassermann. All rights reserved.